01
Neurodegeneration
Can we take aggregates apart, instead of slowing their spread?
Targeting the aggregates behind Alzheimer’s, Parkinson’s, ALS and prion disease.
Frontier research · Las Vegas
Drug discovery from first principles.
A research company using AI-assisted, novel mathematics to find new angles on medicine’s oldest problems.
Fig. 01
Intact
01 The problem
Most drugs are designed the same way: find a protein, build a key to fit its lock.
It’s slow, it’s expensive, and it breaks down when the target mutates, hides or has no lock at all. The usual answer is more of the same: more compounds, more compute, more trials.
Infection
Virusesevolve around their drugs.
Resistance
Bacteriabuild resistance.
Oncology
Cancersrewire themselves.
Neurology
Misfolded proteinsin Alzheimer’s and Parkinson’s have resisted decades of effort.
02 Our approach
We don’t brute-force biology.
The standard playbook is scale: screen more molecules, train bigger models on past drugs, and hope something fits. We take a different posture. We work at the frontier of mathematics, with AI as an instrument, to describe disease in terms no one has written down before. A new description gives a new angle, and new angles are how old problems finally move.
Brute force asks
How many more molecules can we screen?
We ask
What question hasn’t anyone thought to compute?
Novel mathematics
New descriptions, not bigger searches.
When a problem has resisted decades of effort, we assume the description is the bottleneck, and we go looking for a better one.
AI-assisted
AI as an instrument, not an oracle.
We use AI to explore, check and accelerate the work, while our models stay grounded in physics and mathematics rather than in pattern-matching on the past.
One foundation
One way of thinking, every program.
The same foundations serve neurology, infection and oncology. Moving into a new disease area means asking a new question, not building a new company.
03 Research programs
Five programs. One central question each.
02
Broad-spectrum antivirals
Can one mechanism work across virus families?
Rather than one strain at a time, a mechanism that isn’t tied to any single viral protein, so a mutation alone doesn’t route around it.
03
Next-generation antibiotics
What can’t a bacterium give up without dying?
Aiming at exactly that, to close the usual escape route to resistance.
04
Precision oncology
Which patients will respond, before treatment begins?
Matching therapy to the individual tumor, rather than to the average patient.
05
Molecular targeting
Where exactly is a structure weakest?
Mapping that point precisely, so a drug can act where it does the most good with the least collateral.
04 Careers
Pioneers wanted.
We’re building a team of mathematicians, physicists, biologists and engineers who would rather find a new angle than run the old one faster. If an age-old problem has always bothered you, we should talk.
Mathematicians
Geometry, topology, dynamical systems. People who invent the tools, not just apply them.
Introduce yourself →Physicists
Statistical mechanics and biophysics, turning molecular behavior into something computable.
Introduce yourself →Computational biologists
Protein structure, aggregation, host–pathogen and tumor biology.
Introduce yourself →Machine learning researchers
AI that helps search, prove and check, not just predict.
Introduce yourself →Chemists
Medicinal and structural chemists who turn a computed angle into a molecule.
Introduce yourself →Research engineers
Fast, verifiable scientific software built to the standard of a lab notebook.
Introduce yourself →05 Where we are
Early, deliberate, and building toward the lab.
Computational discoveryNow
Laboratory validationBuilding partnerships
New angles on age-old problems.
For investors, research labs and collaborators who want to test a different starting point for drug discovery.
[email protected] →